Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Allarity Therapeutics, Inc. (ALLR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.2371-0.0239 (-9.16%)
At close: 04:00PM EST
0.2400 +0.00 (+1.22%)
After hours: 07:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2610
Open0.2610
Bid0.2420 x 1100
Ask0.2432 x 1100
Day's Range0.2371 - 0.2610
52 Week Range0.2000 - 9.0000
Volume1,447,713
Avg. Volume2,179,105
Market Cap3.421M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0570
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • InvestorPlace

    6 F-Rated Penny Stocks Not Worth Your Dime

    As the adage goes, “where there’s risk, there’s reward.” Unfortunately, this is not universal when it comes to penny stocks. While there are plenty of stocks in “penny territory” (under $5 per share) that are strong opportunities, there are also scores of low-priced names best characterized as penny stocks to sell. When it comes to risk/reward, names in this category offer a lot of former, but an inadequate amount of latter. For the most part, stocks at this price level are one of two things. Th

  • GlobeNewswire

    Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

    Press release Boston, MA U.S.A. (January 20, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today announced that the Company’s 2023 Annual Meeting of Stockholders (the “Meeting”), on January 19, 2023, at 1:00 p.m. (Eastern Time) was adjourned without any business being conducted. The Meeting was adjourned until Frid

  • GlobeNewswire

    Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date

    PRESS RELEASE Boston, MA U.S.A. (December 1, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that the Company’s adjourned 2022 Annual Stockholders Meeting (“2022 ASM”) set for December 2, 2022 has been cancelled and a new meeting date for the Annual Stockholders Meeting (“2023 ASM”) will be held, as

Advertisement
Advertisement